High serum YKL-40 level is associated with poor prognosis in patients with lung cancer
High serum YKL-40 level is associated with poor prognosis in patients with lung cancer
Öz: Introduction: YKL-40 is a glycoprotein that plays role in inflammation and malignant processes. High serum YKL-40 levels areassociated with short survive in cancer and chronic obstructive pulmonary disease (COPD) is another reason to increase its’ level.However, limited knowledges are known in YKL-40 along with lung cancer and COPD.Materials and Methods: One hundred patients were involved tostudy with lung cancer (84 men, 16 women, and median age 62).Results were compared with 30 healthy volunteers. Thirteenpatients were small cell lung cancer (SCLC), 87 patients were nonsmall cell lung cancer (NSCLC). 62% of patients were inoperable.Results: Median YKL-40 level was 222.7 ± 114.1 ng/mL in patientsand was 144.5 ± 105.7 ng/mL in controls (p< 0.001). Stage, tumour size, lymph node involvement and distant metastasis weren’t associated with serum YKL-40 level. Above all cut-off values(133.159 and 162 ng/mL) survival was shorter (p> 0.05). Patients with COPD had worse survive above all cut-off values (p< 0.05),especially according to 133 ng/mL (p= 0.01).Conclusion: YKL-40 level is useful in lung cancer however it’s not related to cell type and prognosis. It is associated with poor prognosis in lung cancer patients with COPD.
Anahtar Kelime: Yüksek serum YKL-40 düzeyi akciğer kanserinde kötü prognozla ilişkilidir
Öz: Giriş: YKL-4 inflamasyon ve malign süreçlerde rol oynayan bir glikoproteindir. Yüksek YKL-40 düzeyi inflamasyonda görüldüğü gibi kanserde kısa yaşam beklentisiyle ilişkilidir. Akciğer kanseri ve kronik obstrüktif akciğer hastalığı (KOAH)’nın serum YKL-40 düzeyi ile ilişkisinin birlikte incelendiği yayın sayısı kısıtlıdır. Materyal ve Metod: Çalışmaya 84 erkek ve 16 kadın olmak üzere 100 hasta dahil edildi. Yaş ortalaması 62 idi. Sonuçlar 30 sağlıklı gönüllü ile karşılaştırıldı. Hastalardan 13 tanesi küçük hücreli akciğer kanseri (KHAK) 87 küçük hücre dışı akciğer kanseri (KHDAK) tanısı aldı. Yüz hastanın 42’sinde KOAH eşlik ediyordu. Bulgular: Hasta grupta ortalama YKL-40 düzeyi 229 ± 110.7 ng/mL iken kontrol grubunda 114.5 ± 105.7 ng/mL saptandı (p< 0.001). Evre, tümör çapı, nodal infiltrasyon ve uzak metastazla YKL-40 düzeyi arasında ilişki saptanmadı. Tüm eşik değerler üzerinde (133.159 ve 162 ng/mL) yaşam süresi daha kısa bulundu (p> 0.05). Özellikle 133 ng/mL‘ye göre KOAH tanılı 42 hastada KOAH olmayanlara göre yaşam süresi anlamlı derecede daha kısaydı (p= 0.01). Sonuç: YKL-40 akciğer kanserinde yararlı bir belirteç ancak hücre tipi ve yaşam süresiyle ilişkisiz. KOAH’ın eşlik ettiği akciğer kanserli hastalarda ise yüksek serum düzeyleri kötü prognozla ilişkili bulunmuştur.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004;3:391-400.
- Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer. Expert Opin Ther Targets 2007;11:219-34.
- Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006;12:5698-704.
- Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-21.
- Choi IK, Kım YH, Kım JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced nonsmall cell lung cancer. Acta Oncologica 2010;49:861-4.
- Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-40.
- Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
- Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194- 202.
- Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008;181;5167-73.
- Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9:e96384.
- Kırankaya Güneş A, Gül Ş, Tutar N, Özgül MA, Çetinkaya E, Zengi O, et al. The place of YKL-40 in non-small cell lung cancer. Tuberk Toraks 2014;62:273-8.
| APA | ÇİLEDAĞ A, AKIN KABALAK P, ÇELİK G, DEMİR N, YÜKSEL C, KÖYCÜ G, ÖZTUNA D, RAD A, KAYA A, KUTLAY H, SAVAŞ İ, NUMANOĞLU N (2018). High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. , 273 - 279. 10.5578/tt.67319 |
| Chicago | ÇİLEDAĞ Aydın,AKIN KABALAK Pınar,ÇELİK GÖKHAN,DEMİR Nalan,YÜKSEL CABİR,KÖYCÜ Gözde,ÖZTUNA Derya GÖKMEN,RAD Abbas Yousefi,KAYA AKIN,KUTLAY Hakan,SAVAŞ İsmail,NUMANOĞLU Numan High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. (2018): 273 - 279. 10.5578/tt.67319 |
| MLA | ÇİLEDAĞ Aydın,AKIN KABALAK Pınar,ÇELİK GÖKHAN,DEMİR Nalan,YÜKSEL CABİR,KÖYCÜ Gözde,ÖZTUNA Derya GÖKMEN,RAD Abbas Yousefi,KAYA AKIN,KUTLAY Hakan,SAVAŞ İsmail,NUMANOĞLU Numan High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. , 2018, ss.273 - 279. 10.5578/tt.67319 |
| AMA | ÇİLEDAĞ A,AKIN KABALAK P,ÇELİK G,DEMİR N,YÜKSEL C,KÖYCÜ G,ÖZTUNA D,RAD A,KAYA A,KUTLAY H,SAVAŞ İ,NUMANOĞLU N High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. . 2018; 273 - 279. 10.5578/tt.67319 |
| Vancouver | ÇİLEDAĞ A,AKIN KABALAK P,ÇELİK G,DEMİR N,YÜKSEL C,KÖYCÜ G,ÖZTUNA D,RAD A,KAYA A,KUTLAY H,SAVAŞ İ,NUMANOĞLU N High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. . 2018; 273 - 279. 10.5578/tt.67319 |
| IEEE | ÇİLEDAĞ A,AKIN KABALAK P,ÇELİK G,DEMİR N,YÜKSEL C,KÖYCÜ G,ÖZTUNA D,RAD A,KAYA A,KUTLAY H,SAVAŞ İ,NUMANOĞLU N "High serum YKL-40 level is associated with poor prognosis in patients with lung cancer." , ss.273 - 279, 2018. 10.5578/tt.67319 |
| ISNAD | ÇİLEDAĞ, Aydın vd. "High serum YKL-40 level is associated with poor prognosis in patients with lung cancer". (2018), 273-279. https://doi.org/10.5578/tt.67319 |
| APA | ÇİLEDAĞ A, AKIN KABALAK P, ÇELİK G, DEMİR N, YÜKSEL C, KÖYCÜ G, ÖZTUNA D, RAD A, KAYA A, KUTLAY H, SAVAŞ İ, NUMANOĞLU N (2018). High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. Tüberküloz ve Toraks, 66(4), 273 - 279. 10.5578/tt.67319 |
| Chicago | ÇİLEDAĞ Aydın,AKIN KABALAK Pınar,ÇELİK GÖKHAN,DEMİR Nalan,YÜKSEL CABİR,KÖYCÜ Gözde,ÖZTUNA Derya GÖKMEN,RAD Abbas Yousefi,KAYA AKIN,KUTLAY Hakan,SAVAŞ İsmail,NUMANOĞLU Numan High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. Tüberküloz ve Toraks 66, no.4 (2018): 273 - 279. 10.5578/tt.67319 |
| MLA | ÇİLEDAĞ Aydın,AKIN KABALAK Pınar,ÇELİK GÖKHAN,DEMİR Nalan,YÜKSEL CABİR,KÖYCÜ Gözde,ÖZTUNA Derya GÖKMEN,RAD Abbas Yousefi,KAYA AKIN,KUTLAY Hakan,SAVAŞ İsmail,NUMANOĞLU Numan High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. Tüberküloz ve Toraks, vol.66, no.4, 2018, ss.273 - 279. 10.5578/tt.67319 |
| AMA | ÇİLEDAĞ A,AKIN KABALAK P,ÇELİK G,DEMİR N,YÜKSEL C,KÖYCÜ G,ÖZTUNA D,RAD A,KAYA A,KUTLAY H,SAVAŞ İ,NUMANOĞLU N High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. Tüberküloz ve Toraks. 2018; 66(4): 273 - 279. 10.5578/tt.67319 |
| Vancouver | ÇİLEDAĞ A,AKIN KABALAK P,ÇELİK G,DEMİR N,YÜKSEL C,KÖYCÜ G,ÖZTUNA D,RAD A,KAYA A,KUTLAY H,SAVAŞ İ,NUMANOĞLU N High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. Tüberküloz ve Toraks. 2018; 66(4): 273 - 279. 10.5578/tt.67319 |
| IEEE | ÇİLEDAĞ A,AKIN KABALAK P,ÇELİK G,DEMİR N,YÜKSEL C,KÖYCÜ G,ÖZTUNA D,RAD A,KAYA A,KUTLAY H,SAVAŞ İ,NUMANOĞLU N "High serum YKL-40 level is associated with poor prognosis in patients with lung cancer." Tüberküloz ve Toraks, 66, ss.273 - 279, 2018. 10.5578/tt.67319 |
| ISNAD | ÇİLEDAĞ, Aydın vd. "High serum YKL-40 level is associated with poor prognosis in patients with lung cancer". Tüberküloz ve Toraks 66/4 (2018), 273-279. https://doi.org/10.5578/tt.67319 |
